📢 New @ASE360 Guidelines on Diastolic Function are out, and Ultromics is cited!. Our study on EchoGo® Heart Failure is referenced, highlighting its role in supporting #HFpEF detection from a single echo view. Full guidelines: #CardioTwitter #EchoFirst

We will be at the Charleston HFpEF Conference showcasing our EchoGo® Heart Failure and Amyloidosis modules, the first AI-based tools capable of detecting #HFpEF & #Amyloidosis from routine echocardiograms.

“I think EchoGo® Amyloidosis is going to be very important because we have data that suggest a significant number of patients with HFpEF can have underlying cardiac amyloidosis". Learn more about EchoGo® Amyloidosis in a new interview with Dr. Andres Schuster at @HarringtonHVI:

In a new interview, Dr. Andres Schuster at @HarringtonHVI discusses recent cases where EchoGo® Amyloidosis supported the positive identification of patients with cardiac amyloidosis. Learn more how EchoGo® Amyloidosis, powered by #AI, identifies cardiac #amyloidosis, supporting

EchoGo® Heart Failure detects #HFpEF with excellent sensitivity and specificity. Learn more about its impressive clinical performance in the new interview with Dr. Andres Schuster from @HarringtonHVI in this month’s Cath Lab Digest: #EchoFirst

Patient symptoms aren’t matching the diastology? EchoGo® Heart Failure can help in the diagnostic process. Dr. Andres Schuster from @HarringtonHVI shares his experience using EchoGo® Heart Failure, powered by AI, to help detect #HFpEF. Read more in Cath Lab Digest:

An Interview with Dr. Andres Schuster. Dr. Andres Schuster @HarringtonHVI on how Ultromics supports his team to seamlessly implement EchoGo® Heart Failure into workflow for #HFpEF care.

Cardiac #Amyloidos is frequently missed or diagnosed too late, often due to overlapping symptoms and limitations in current pathways. We break down why it’s challenging to diagnose — and the limitations of current tools. #CardioTwitter .

Cardiac #Amyloidosis is a progressive, often underdiagnosed cause of #HeartFailure with serious impact on patient quality of life. Learn more about what Cardiac Amyloidosis is, how it’s diagnosed, and how it's treated:.👉

Is this Cardiac Amyloidosis? Many heart conditions are challenging to detect, but AI can help uncover them. Dr. Patricia A. Pellikka shows how #EchoGo identifies disease from an echo videoclip: #CardioTwitter

Ultromics featured research at Heart Failure 2025 📣. Our Director of Clinical Science Ashley Akerman presented:.Three Rules to Find Them All: Clinical Risk Scores in Heart Failure With Preserved Ejection Fraction (HFpEF), highlighting the benefit of combining AI with traditional

We're at #HeartFailure2025! Our Director of Clinical Science @ presents:.Three Rules to Find Them All – exploring how #AI supports #HFpEF management.📍 Moderated ePosters 3, 18 May, 12:00–12:45,

EchoGo® Amyloidosis can improve detection of patients with Cardiac Amyloidosis — an often-missed disease and a leading cause of Heart Failure. Dr. Faizi A. Jamal shares why this new tool is set to transform care and impact outcomes. Learn more: